You are here:
NICE
NICE Guidance
Published Guidance
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Technology appraisal guidance
Reference number:
TA885
Published:
03 May 2023
This guidance has been updated and replaced by
NICE technology appraisal guidance 939
.